Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Adding a new indication for the CAR T cell therapy could help BMS offset the loss-of-exclusivity headwinds it faces in the ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.

Cobenfy comes as a capsule. It received Food and Drug Administration approval on Sept. 26 as a treatment for schizophrenia, then launched onto the U.S. market in late October. By Bristol Myers ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The firm’s Cobenfy drug for schizophrenia is the first of its kind in decades. Bristol-Myers Squibb Company (NYSE:BMY)’s shares have gained 24% over the past year as they have benefited from ...

(Reuters) -Bristol Myers Squibb on Thursday posted better-than-expected fourth-quarter earnings, but said its 2025 revenue ...